September 29, 2020

Cardiac Dimensions Receives Financing to Accelerate Commercialization of Carillon System in Europe and Australia

September 29, 2020—Cardiac Dimensions announced the company has closed a $17.5 million Series C financing to support the commercialization of the company’s Carillon mitral contour system to treat functional mitral regurgitation (FMR) in patients with heart failure.

According to the company, the financing will be used to accelerate commercial sales of the Carillon system in Europe and to allow for expansion into other geographies such as Australia. On September 2, 2020, the company announced that Australia’s Therapeutic Goods Administration approved the Carillon system for commercial use in FMR patients with mild to severe MR. The Carillon system has European CE Mark approval and was first launched in Europe in 2012. In the United States, the device is limited to investigational use and is being studied in the CARILLON pivotal trial, which commenced enrollment in 2018.

Cardiac Dimensions noted that all existing shareholders participated in the round, including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira Ventures, and M. H. Carnegie & Co.


September 30, 2020

SCAI Recommends Changes to CMS Proposed Rules and Payment Plans for 2021

September 28, 2020

SCAI Bifurcation Club Formed to Promote Worldwide Excellence in Coronary Artery Bifurcation Interventions